Search research articles
Contact Us
Filters
Showing results (221-230 of 234) with videos related to
Page
of 24
Sort By:
NPJ Vaccines
|
July 16, 2025
Surveillance and follow up outcomes of myocarditis after mRNA COVID-19 vaccination in Australia
Lucy Deng, Amanda Van Eldik, Megan O'Moore, et al.
Neurobiology of Disease
|
May 15, 2021
Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates
Peer B Jacobson, Robin Goody, Matthew Lawrence, et al.
Journal of Alzheimer'S Disease : JAD
|
October 9, 2010
A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease
Sofia Tzimopoulou, Vincent J Cunningham, Thomas E Nichols, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
October 10, 2012
Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development
Adam L Boxer, Michael Gold, Edward Huey, et al.
The Lancet Regional Health. Western Pacific
|
September 13, 2023
The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1-S (AZD1222) vaccination and case outcomes in Australia: a population-based study
Huyen A Tran, Lucy Deng, Nicholas Wood, et al.
Heart Rhythm
|
September 4, 2012
2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management
, , , et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
November 1, 2019
New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures
Adam L Boxer, Michael Gold, Howard Feldman, et al.
The Lancet. Neurology
|
May 31, 2014
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial
Adam L Boxer, Anthony E Lang, Murray Grossman, et al.
Biorxiv : the Preprint Server for Biology
|
August 23, 2023
An oligodendrocyte silencer element underlies the pathogenic impact of lamin B1 structural variants
Bruce Nmezi, Guillermo Rodriguez Bey, Talia DeFrancesco Oranburg, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
September 28, 2021
Current directions in tau research: Highlights from Tau 2020
Claire Sexton, Heather Snyder, Dirk Beher, et al.
Page
of 24
Search research articles
Search
Showing results (221-230 of 234) with videos related to
Sort By:
Page
of 24
NPJ Vaccines
|
July 16, 2025
Surveillance and follow up outcomes of myocarditis after mRNA COVID-19 vaccination in Australia
Lucy Deng, Amanda Van Eldik, Megan O'Moore, et al.
Neurobiology of Disease
|
May 15, 2021
Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates
Peer B Jacobson, Robin Goody, Matthew Lawrence, et al.
Journal of Alzheimer'S Disease : JAD
|
October 9, 2010
A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease
Sofia Tzimopoulou, Vincent J Cunningham, Thomas E Nichols, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
October 10, 2012
Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development
Adam L Boxer, Michael Gold, Edward Huey, et al.
The Lancet Regional Health. Western Pacific
|
September 13, 2023
The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1-S (AZD1222) vaccination and case outcomes in Australia: a population-based study
Huyen A Tran, Lucy Deng, Nicholas Wood, et al.
Heart Rhythm
|
September 4, 2012
2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management
, , , et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
November 1, 2019
New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures
Adam L Boxer, Michael Gold, Howard Feldman, et al.
The Lancet. Neurology
|
May 31, 2014
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial
Adam L Boxer, Anthony E Lang, Murray Grossman, et al.
Biorxiv : the Preprint Server for Biology
|
August 23, 2023
An oligodendrocyte silencer element underlies the pathogenic impact of lamin B1 structural variants
Bruce Nmezi, Guillermo Rodriguez Bey, Talia DeFrancesco Oranburg, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
September 28, 2021
Current directions in tau research: Highlights from Tau 2020
Claire Sexton, Heather Snyder, Dirk Beher, et al.
Page
of 24